Strides Arcolab shares plunge over 5 per cent

Image
Press Trust of India Mumbai
Last Updated : Jun 18 2015 | 12:13 PM IST
Shares of Strides Arcolab fell by over 5 per cent today after the government rejected proposal of the drug firm to issue shares to non-resident and resident equity shareholders of Shasun Pharmaceuticals.
The scrip declined by 5.4 per cent to Rs 1,090.80 at the BSE.
On the NSE, it lost 5 per cent to Rs 1,095.25.
The government yesterday rejected proposal from Strides Arcolab for issuing shares to non-resident and resident equity shareholders of Shasun Pharmaceuticals Ltd under a scheme of merger.
Proposals for foreign direct investment amounting to around Rs 4,000 crore by four pharma and medical devices firms, including Torrent Pharmaceuticals and Biocon's research services arm Syngene, were yesterday approved by the government.
Meanwhile, in the broader market, the BSE 30-share Sensex was trading at 27,083.51, up 250 points.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 18 2015 | 12:13 PM IST

Next Story